Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Nuvation Bio Inc. (NUVB) had Consolidated Net Income/Loss of $-62.84M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$31.69M |
|
$-62.84M |
|
$9.47M |
|
$22.22M |
|
$82.72M |
|
$-51.04M |
|
$-11.80M |
|
$-62.84M |
|
$-62.84M |
|
$-62.84M |
|
$-62.84M |
|
|
Consolidated Net Income/Loss |
$-62.84M |
$-62.84M |
|
$-51.04M |
|
$-50.15M |
|
348.77M |
|
348.77M |
|
$-0.18 |
|
$-0.18 |
|
| Balance Sheet Financials | |
$726.43M |
|
$0.71M |
|
$18.07M |
|
$744.50M |
|
$86.75M |
|
$242.62M |
|
$403.88M |
|
$490.64M |
|
$253.86M |
|
$243.57M |
|
$253.86M |
|
349.82M |
|
| Cash Flow Statement Financials | |
$-37.90M |
|
$-37.65M |
|
$170.57M |
|
$164.09M |
|
$258.60M |
|
$94.52M |
|
$19.49M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.37 |
|
-- |
|
-- |
|
0.49 |
|
0.98 |
|
70.11% |
|
-161.06% |
|
-161.06% |
|
-- |
|
-198.31% |
|
-198.31% |
|
$-38.20M |
|
-- |
|
-- |
|
-- |
|
0.04 |
|
0.48 |
|
1.00 |
|
90.08 |
|
-24.75% |
|
-25.80% |
|
-8.44% |
|
-12.66% |
|
$0.73 |
|
$-0.11 |
|
$-0.11 |
|